Geron has been granted a patent for crystalline solids of specific compounds and methods for their preparation. The patent includes the creation of single crystals and conversion processes. GlobalData’s report on Geron gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Geron, Peptide pharmacophores was a key innovation area identified from patents. Geron's grant share as of May 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for crystalline solid of compound of formula i
A recently granted patent (Publication Number: US11987540B2) discloses a crystalline solid of a compound of Formula I, as outlined in the claims. The crystalline solid exhibits specific thermal properties, including a first endotherm at 79.3° C. and a second endotherm at approximately 102.5° C. as determined by differential scanning calorimetry (DSC). Additionally, the thermogravimetric analysis (TGA) of the crystalline solid shows a single weight loss step starting at around 200.5° C.
Furthermore, the patent claims specify that the second endotherm observed in the crystalline solid is characterized by a single peak endotherm. These unique thermal characteristics provide valuable insights into the stability and behavior of the crystalline solid, which can have implications for its potential applications in various industries. The detailed analysis of the compound's thermal properties as outlined in the patent claims highlights the innovative nature of the invention and its potential for further development and commercialization.
To know more about GlobalData’s detailed insights on Geron, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.